LENZ Ebitda from 2010 to 2024

LENZ Stock   35.50  1.18  3.44%   
LENZ Therapeutics EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, LENZ Therapeutics EBITDA regression line of annual values had significance of  0.0001 and arithmetic mean of (31,613,120). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-122.2 M
Current Value
-116.1 M
Quarterly Volatility
48.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LENZ Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LENZ Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 48 K or Other Operating Expenses of 55.6 M, as well as many indicators such as Price To Sales Ratio of 6.57, Dividend Yield of 0.0 or PTB Ratio of 0.58. LENZ financial statements analysis is a perfect complement when working with LENZ Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LENZ Therapeutics Correlation against competitors.
For more information on how to buy LENZ Stock please use our How to Invest in LENZ Therapeutics guide.

Latest LENZ Therapeutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of LENZ Therapeutics over the last few years. It is LENZ Therapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LENZ Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

LENZ Ebitda Regression Statistics

Arithmetic Mean(31,613,120)
Coefficient Of Variation(152.32)
Mean Deviation42,112,160
Median(29,000)
Standard Deviation48,152,885
Sample Variance2318.7T
Range122.2M
R-Value(0.83)
Mean Square Error756.8T
R-Squared0.70
Significance0.0001
Slope(8,988,809)
Total Sum of Squares32461.8T

LENZ Ebitda History

2024-116.1 M
2023-122.2 M
2022-97.3 M
2021-70 M
2020-68.2 M

About LENZ Therapeutics Financial Statements

LENZ Therapeutics investors use historical fundamental indicators, such as LENZ Therapeutics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LENZ Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-122.2 M-116.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LENZ Stock Analysis

When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.